As previously reported, Maxim downgraded Iterum Therapeutics (ITRM) to Hold from Buy. The firm cites the company’s filing reporting its shares are scheduled to be delisted from Nasdaq on 3/5/26 due to non-compliance with listing requirements, unless the company requests a hearing and regains compliance, the analyst tells investors in a research note. Maxim adds that based on its cash burn estimates, Iterum needs to raise capital in 2Q26 which could be further challenging if delisting occurs as well as the distressed valuation.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITRM:
- Iterum Therapeutics downgraded to Hold from Buy at Maxim
- Iterum Therapeutics Appeals Nasdaq Delisting, Explores Strategic Alternatives
- Morning News Wrap-Up 3/3/26: Tuesday’s Biggest Stock Market Stories!
- Why Is Iterum Therapeutics Stock (ITRM) Down Today?
- Iterum Therapeutics Faces Nasdaq Delisting, Weighs Strategic Options